ISAD × WHO day

Preliminary invited participants and draft program

Purpose and general structure of the day 1.

The ISAD × WHO day will be held on Friday, 16 October 2026, immediately before the Rajka Symposium in Beijing. It will provide a structured forum to advance two closely linked ISAD priorities in atopic dermatitis: the development of an international Treat-to-Target consensus project and the continuation of ISAD–WHO-related work on access to care and essential medicines.

All invited participants listed below are invited for the full day. The day will have two distinct formats:

1. Morning session – closed to industry

This session will be devoted to the ISAD-led Treat-to-Target consensus project in atopic dermatitis. It will focus on scope, terminology, methodology, patient-centered outcomes, global feasibility, and the next steps toward Delphi consensus development.

2. Afternoon session – open to industry

This session will review ongoing ISAD–WHO-related projects, access-to-medicines priorities, and preparation for the 2027 WHO Essential Medicines List cycle. Industry participants will be invited separately and may contribute actively during the moderated discussions.

A short report from the closed morning Treat-to-Target workshop will be presented during the afternoon session. A further concise report from the day will also be presented at the main Rajka meeting.

Preliminary invited participants by region of origin 2.

Roles of ISAD, IEC, GADA, WHO, ILDS, and Industry 3.

ISAD

ISAD will convene the meeting and coordinate the overall scientific agenda. ISAD will lead the Treat-to-Target consensus project, patient-centered discussions, regional guideline links, and reporting to the main Rajka meeting.

IEC

IEC will be involved throughout the day, especially in the Treat-to-Target consensus development and in ensuring alignment with international AD expertise.

GADA

GADA will contribute to global epidemiology, disease burden, metrics, and implementation perspectives of the T2T project. Through Carsten Flohr, GADA will also provide the operational link with ILDS for the access-to-medicines project.

WHO

WHO via Lorenzo Moja will contribute to the discussion on essential medicines and access to care, particularly in relation to the 2027 WHO Essential Medicines List process.

ILDS

ILDS, via Carsten Flohr/GADA, will be in command of the main project for possible inclusion of methotrexate and dupilumab in the 2027 WHO Essential Medicines List cycle (expected submission in September 2027).

Industry

Industry participants will be invited separately for the afternoon session. They will not participate in the closed morning workshop. In the afternoon, they will not be limited to observer status and may contribute actively during moderated discussions.

Preliminary program of the day

Please note all timings are based on Beijing time zone.
➜ China Standard Time (CST) – UTC+08:00

	Friday, October 16th, 2026 — ISAD × WHO day #CCIFC
13:45	W1.1	Welcome Address
13:45	OBJ1	Opening Remarks + Patient Testimonials Objective: Anchor the workshop in the patient experience Jean-François STALDER, France
13:50	W1.2	Digital Tools and Shared Monitoring
13:50	AV1	Avatar Case 1 A patient relying on social media and AI tools, facing misinformation, questioning medical authority, and struggling with adherence
13:55	KN1	Dermatological Perspective on Digital Technology Clinical reasoning, longitudinal follow-up, risks of over-digitization, doctor–patient relationship, clinical limits Peter LIO, United States of America
14:25	AV2	Avatar Case 2 Patient using Eczema Care+ for monitoring, facing uncertainty and information overload
14:30	KN2	Eczema Care Plus: Example Digital Tool Objectives, data, integration into care pathways, implementation conditions Catherine JEAN-DECOSTER, France
14:50	IR1	Empowerment vs overload, social media influence, responsibility, confidentiality, TOPICOP Interactive Roundtable – Plenary Discussion
15:00	IR2	Two groups; each formulates 3 criteria for rational use of digital tools Interactive Roundtable – Small Group Work
15:30	IR3	Consolidation into a shared set of criteria Interactive Roundtable – Collective Validation
15:35	BS2	Break Session 2 (free time without presentation)55 min. Refreshment Break & Visit Exhibits ➜ Check the Schedule
16:30	W1.3	Integrative Medicine and Therapeutic Alliance
16:30	OBJ2	Integrative medicine reflects real patient behavior; need for structured and safe integration Introduction Jean-François STALDER, France
16:40	KN3	Scientific data, articulation with biomedicine/psychology, benefits, limits, safety Integrative Medicine Framework Trevor ERIKSON, Canada
17:00	AV3	Avatar Case 3 - “Integrative Cultural Pathway” (Beijing patient) - “Diet/Supplement Spiral” (parent of child with AD) - “Invisible Burden” (adult with severe symptoms)
17:10	IR4	Patient expectations, uncertainty, therapeutic rupture, cultural issues Interactive Roundtable – Plenary Discussion
17:30	IR5	Three groups; each defines 3 criteria for safe integration of alternative approaches Interactive Roundtable – Small Group Work
17:50	IR6	Comparison and synthesis of group outputs Interactive Roundtable – Plenary Consolidation
18:00	CSS6	Synthesis and Consensus (Sessions 1 & 2) Clarification of consensual principles

Expected outputs of the day 4.

The expected outputs of the ISAD × WHO day are:

1. A clear statement of the scope and next steps of the ISAD Treat-to-Target consensus project.
2. Agreement on the main domains to be considered in the Delphi process.
3. Integration of patient-centered medicine and patient-reported outcomes into the T2T framework.
4. A short internal report from the closed morning workshop.
5. A shared update on ISAD–WHO-related projects and access-to-care priorities.
6. 2027 EML strategy for AD, including the ILDS project on methotrexate and dupilumab, and projects for EML 2029
7. Regional input on implementation challenges in Africa, Asia-Pacific, the Middle East, and Latin America.
8. A structured discussion with industry participants on evidence generation, affordability, responsible access, and global AD care.
9. A concise report to be presented at the main Rajka meeting on Monday 19th (afternoon).

Points still to be completed 5.

1. Add the industry participant list when available.
2. Confirm final availability of all invited participants.
3. Confirm the final local Chinese host roles.